(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Top 15 Style Creators Changing the Business - 2Satellite space quiz: What's orbiting Earth?
- 3See a half-lit moon shine among the stars of Aquarius on Nov. 27
- 4Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)
- 5'All Her Fault' ending explained: The shocking conclusion to the psychological thriller inspired by true events
- 4 DSLR Cameras for Amateurs in 2024
- Linda Hamilton, 69, says she doesn't want to 'chase longevity'
- Spots to Go Hang Floating
- Top Smoothie Flavor: What's Your Mix?
- Visual communication Programming for Fledglings
- Paratroopers kill terrorist who threw rocks at Israeli citizens, soldiers near Ofra in West Bank
- Which Shrewd Home Gadget Can't You Reside Without?
- Picking the Right Doctor prescribed Medication Inclusion in Senior Protection.
- Home Mechanization Frameworks for Brilliant Residing
